Millennium Management LLC Has $11.40 Million Stake in MaxCyte, Inc. (NASDAQ:MXCT)

Millennium Management LLC decreased its holdings in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 34.6% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 2,740,871 shares of the company's stock after selling 1,451,994 shares during the period. Millennium Management LLC owned approximately 2.59% of MaxCyte worth $11,402,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Mirabella Financial Services LLP acquired a new stake in MaxCyte in the fourth quarter worth about $15,392,000. River Global Investors LLP raised its stake in shares of MaxCyte by 57.7% in the fourth quarter. River Global Investors LLP now owns 3,253,192 shares of the company's stock valued at $13,494,000 after purchasing an additional 1,190,630 shares in the last quarter. Cadian Capital Management LP raised its stake in MaxCyte by 14.1% during the fourth quarter. Cadian Capital Management LP now owns 9,344,424 shares of the company's stock worth $38,873,000 after acquiring an additional 1,155,476 shares in the last quarter. AXA S.A. acquired a new position in MaxCyte in the fourth quarter valued at about $4,105,000. Finally, Royce & Associates LP raised its position in shares of MaxCyte by 146.9% during the fourth quarter. Royce & Associates LP now owns 799,873 shares of the company's stock worth $3,327,000 after purchasing an additional 475,949 shares during the period. Hedge funds and other institutional investors own 68.81% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on MXCT shares. BTIG Research set a $6.00 price target on MaxCyte and gave the company a "buy" rating in a research note on Wednesday, March 12th. Stifel Nicolaus lowered their price objective on MaxCyte from $11.00 to $9.00 and set a "buy" rating for the company in a research report on Wednesday, March 12th.

MaxCyte Trading Up 8.7%

NASDAQ:MXCT traded up $0.19 during mid-day trading on Tuesday, hitting $2.38. The stock had a trading volume of 1,741,618 shares, compared to its average volume of 593,124. The stock has a 50-day simple moving average of $2.59 and a two-hundred day simple moving average of $3.51. The company has a market capitalization of $253.04 million, a PE ratio of -7.00 and a beta of 1.38. MaxCyte, Inc. has a twelve month low of $2.10 and a twelve month high of $5.26.

MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. The firm had revenue of $10.39 million during the quarter, compared to analysts' expectations of $9.05 million. Sell-side analysts predict that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.